drugset / Trial / NCT00880360
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
Timeline
- Start
- 2007-02
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin diftitox | Protein / enzyme biologic | 12 ug/kg | Intravenous |